

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 5, line 25, as follows:

Substitution of the sequence LTR-IVG (SEQ ID NO: 1) of the activation site of factor X with the sequence VPR-SFR (SEQ ID NO: 3) would make it possible to multiply by 10^5 the rate of cleavage of factor X by thrombin. However, there is a risk that this substitution would be prejudicial to the enzymatic activity of the factor Xa. It is not in fact possible to predict what the enzymatic activity of an activated factor X analogue in which the heavy chain begins with a residue other than isoleucine would be.

Please amend Table II appearing on page 10, as follows:

Primer	Sequences (5'→3')	Th (°C)
1	ACGCGGATCCGCGATGGGGCGCCCACTGCA (<u>SEQ ID NO: 13</u>)	51
2	TCCCCCGGGGGATCAGTTCAGGTCTCCTCGCTGATCAGCTTCTGCTCC TTAATGGAGAGGACGTTA (<u>SEQ ID NO: 14</u>)	51

Please amend the paragraph beginning on page 12, line 24, as follows:

The vector pNUT-ETW (LE BONNIEC et al., J. Biol. Chem., 267, 6970-6976, 1992) expresses a derivative of human prothrombin lacking its "Gla" domain, and fused, at the N-terminal, to the signal peptide of bovine factor V and to a 12 amino acid sequence (EDQVDPRLIDGK; SEQ ID NO: 6), constituting an epitope recognized by the monoclonal antibody HPC-4.

Please amend Table III appearing on page 13, as follows:

Primers	SEQUENCES (5'→3')	Th (°C)
3	TATGCGTGGGCTGGAGCAACC (<u>SEQ ID NO: 15</u>)	62
4	TTATTAGGACAAGGCTGGTGGG (<u>SEQ ID NO: 16</u>)	62
5	CTTCCCATCAATGAGCCGCGG (<u>SEQ ID NO: 17</u>)	62
6	CCGCGGCTCATTGATGGAAAGGATGGCGACCAGTGTGAGACC (<u>SEQ ID NO: 18</u>)	62

Please amend the paragraph beginning on page 14, line 2, as follows:

In native factor X (and also in the GDX-FX derivative), the sequence of the residues P₃-P₂-P₁-P₁'-P₂'-P₃' framing the cleavage site (the cleavage taking place between P₁ and P₁') is LTR-IVG (SEQ ID NO: 1).

Please amend the paragraph beginning on page 14, line 5, as follows:

The six factor X analogues prepared: GDX-IVG, GDX-IFG, GDX-AVG, GDX-IFR, GDX-SVG, GDX-SFR have respectively the sequence P₃-P₂-P₁-P₁'-P₂'-P₃': VPR-IVG (SEQ ID NO: 7), VPR-IFG (SEQ ID NO: 8), VPR-IFR (SEQ ID NO: 9), VPR-AVG (SEQ ID NO: 10), VPR-SVG (SEQ ID NO: 11) and VPR-SFR (SEQ ID NO: 12).

Please amend Table IV appearing on page 14, as follows:

GDX-IVG (s)	AGGGCGACAACACGTGCCTAGGATCGTGGCGGCCAGGAATGCAAG (<u>SEQ ID NO : 19</u>)
GDX-IVG (a)	CTTGCATTCTGGCCGCCACGATCCTAGGCACGTTGTTGTCGCCCT (<u>SEQ ID NO : 20</u>)
GDX-IFG (s)	AGGGCGACAACACGTGCCTAGGATCTCGGGGCCAGGAATGCAAG (<u>SEQ ID NO : 21</u>)
GDX-IFG (a)	CTTGCATTCTGGCCGCCAGAGATCCTAGGCACGTTGTTGTCGCCCT (<u>SEQ ID NO : 22</u>)
GDX-IFR (s)	AGGGCGACAACACGTGCCTAGGATCTCAGGGGCCAGGAATGCAAG (<u>SEQ ID NO : 23</u>)
GDX-IFR (a)	CTTGCATTCTGGCCCTGAAGATCCTAGGCACGTTGTTGTCGCCCT (<u>SEQ ID NO : 24</u>)
GDX-SFR (s)	AGGGCGACAACACGTGCCTAGGAGCTTCAGGGGCCAGGAATGCAAG (<u>SEQ ID NO : 25</u>)
GDX-SFR (a)	CTTGCATTCTGGCCCTGAAGCTCCTAGGCACGTTGTTGTCGCCCT (<u>SEQ ID NO : 26</u>)
GDX-SVG (s)	CAACGTGCCTAGGAGCGTGGCGGCCAGG (<u>SEQ ID NO : 27</u>)
GDX-SVG (a)	CCTGGCCGCCACGCTCCTAGGCACGTTG (<u>SEQ ID NO : 28</u>)
GDX-AVG (s)	CCTGAGAGGGCGACAACACGTGCCTAGGGCGTGGCGGCCAGGAATGCAAGG (<u>SEQ ID NO : 29</u>)
GDX-AVG (a)	CCTGCATTCTGGCCGCCACGGCCCTAGGCACGTTGTTGTCGCCCTCTCAGG (<u>SEQ ID NO : 30</u>)

Please delete the original Sequence Listing.

Page 44 (Abstract), after the last line, beginning on a new page, please insert the attached substitute Sequence Listing.